Related Experiment Videos

Prognostic variables and survival in pediatric acute lymphoblastic leukemias: cancer institute experience

V Shanta1, V Maitreyan, T G Sagar

  • 1Division of Medical Oncology, Cancer Institute, Madras, India.

Insights

This study analyzed prognostic factors in pediatric acute lymphoblastic leukemia (ALL). Age at diagnosis was the only independent risk factor, with survival rates comparable to similar international studies.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Research

Background:

  • Pediatric acute lymphoblastic leukemia (ALL) presents unique prognostic challenges.
  • Many patients in this cohort exhibited multiple high-risk factors at diagnosis.
  • Previous treatment protocols may not have adequately addressed poor-risk ALL characteristics.

Purpose of the Study:

  • To analyze front-line prognostic variables for complete response, continuous complete remission, and disease-free survival in pediatric ALL.
  • To identify independent risk factors influencing outcomes in a poor-prognostic group.
  • To evaluate the efficacy of a pilot treatment protocol for high-risk pediatric ALL.

Main Methods:

  • Analysis of clinical characteristics and prognostic factors in 97 pediatric ALL patients treated between 1983-1988.
  • Utilized the Cox proportional hazard model to assess the significance of prognostic variables.
  • Employed the Kaplan-Meier method for survival data analysis, including relapse-free and event-free survival.

Main Results:

  • Nearly all patients presented with multiple adverse prognostic factors, including age, white blood cell count, blast count, organomegaly, and L2 morphology.
  • Age at presentation was the sole independent risk factor identified.
  • Relapse-free survival was 50.7% and event-free survival was 38.1% at 10 years.

Conclusions:

  • Age is a critical independent prognostic factor in pediatric ALL.
  • The pilot protocol demonstrated comparable survival outcomes to international standards for similar high-risk groups.
  • Further research into optimizing treatment for poor-risk pediatric ALL is warranted.

Related Concept Videos